| Data show that acyl-modified forms of HRAS-like tumor suppressors HRASLS2 and HRASLS3 mimicking lipolytic activity of lecithin retinol acyltransferase LRAT. | None |
| Dose-dependent mutation profile in the c-Ha-ras proto-oncogene of skin tumors in mice initiated with benzo[a]pyrene. | skin, |
| Suppression of apoptosis in C3H mouse liver tumors by activated Ha-ras oncogene. | liver, |
| Ha-ras oncogene effect on DNA content and chromatin supraorganization in benzo[a]pyrene-transformed human breast epithelial cells. | breast, |
| Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis. | bladder, |
| Evidence for a telomere-independent clock limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. | thyroid, |
| [Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection]. | liver, |
| H-ras oncogene mutation in dedifferentiated liposarcoma. Polymerase chain reaction-restriction fragment length polymorphism analysis. | sarcoma, |
| H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis. | sarcoma, |
| Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection. | liver, |
| Transgenic rats carrying human c-Ha-ras proto-oncogene are highly susceptible to N-nitrosomethylbenzylamine induction of esophageal tumorigenesis. | esophageal, |
| A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. | bladder, |
| Ha-ras oncogene mutation associated to progression of papillomavirus induced lesions of uterine cervix. | uterine, |
| Clinical and histopathologic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer. | lung, |
| Genetic alterations in the 61st codon of the H-ras oncogene isolated from archival sections of hepatic hyperplasias, adenomas and carcinomas in control groups of B6C3F1 mouse bioassay studies conducted from 1979 to 1986. | liver, |
| Mutated c-Ha-ras oncogene alters cytokeratin expression in the human breast epithelial cell line MCF-10A. | breast, |
| Stepwise transformation of primary thyroid epithelial cells by a mutant Ha-ras oncogene: an in vitro model of tumor progression. | thyroid, |
| Point mutations in the Ha-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases. | oral |
| The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. | oral |
| Lack of effect of human c-Ha-ras proto-oncogene overexpression on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. | prostate, |